ESPERION THERAPEUTICS INC NE's ticker is ESPR and the CUSIP is 29664W105. A total of 169 filers reported holding ESPERION THERAPEUTICS INC NE in Q2 2019. The put-call ratio across all filers is 1.06 and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2024 | $1,806 | +50.0% | 813,399 | +81.1% | 0.13% | +31.2% |
Q1 2024 | $1,204 | -64.3% | 449,129 | -60.2% | 0.10% | -66.2% |
Q4 2023 | $3,373 | +208.3% | 1,128,149 | +1.0% | 0.28% | +202.1% |
Q3 2023 | $1,094 | +82.6% | 1,116,655 | +159.1% | 0.09% | +56.7% |
Q2 2023 | $599 | +234.6% | 430,922 | +282.8% | 0.06% | +233.3% |
Q1 2023 | $179 | +58.4% | 112,584 | +518.0% | 0.02% | +28.6% |
Q4 2022 | $113 | -100.0% | 18,217 | -22.9% | 0.01% | -51.7% |
Q3 2021 | $285,000 | -45.4% | 23,628 | +17.6% | 0.03% | -65.9% |
Q4 2020 | $522,000 | +7.6% | 20,093 | +54.0% | 0.08% | +4.9% |
Q3 2020 | $485,000 | -31.4% | 13,050 | -14.1% | 0.08% | +2.5% |
Q2 2019 | $707,000 | +55.7% | 15,197 | +67.9% | 0.08% | +154.8% |
Q3 2017 | $454,000 | +1.1% | 9,050 | -6.7% | 0.03% | +6.9% |
Q2 2017 | $449,000 | -65.0% | 9,705 | -73.3% | 0.03% | -58.0% |
Q1 2017 | $1,283,000 | +70.6% | 36,328 | +13.9% | 0.07% | +86.5% |
Q3 2015 | $752,000 | +5.8% | 31,898 | +266.6% | 0.04% | +37.0% |
Q2 2015 | $711,000 | – | 8,700 | – | 0.03% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Meditor Group Ltd | 2,818,835 | $33,967,000 | 11.67% |
PLATINUM INVESTMENT MANAGEMENT LTD | 1,713,176 | $20,644,000 | 0.58% |
Bellevue Group AG | 4,519,164 | $54,455,000 | 0.55% |
Rhenman & Partners Asset Management AB | 622,267 | $7,498,000 | 0.53% |
JACOB ASSET MANAGEMENT OF NEW YORK LLC | 47,534 | $573,000 | 0.21% |
WASATCH ADVISORS LP | 3,274,360 | $39,456,000 | 0.16% |
EMC Capital Management | 27,566 | $246,000 | 0.14% |
PDT Partners, LLC | 120,828 | $1,456,000 | 0.10% |
Virtus ETF Advisers LLC | 17,773 | $214,000 | 0.09% |
Pinz Capital Management, LP | 15,300 | $184,000 | 0.08% |